Cox B, Danta G, Schnieden H, Yuill G M
J Neurol Neurosurg Psychiatry. 1973 Jun;36(3):354-61. doi: 10.1136/jnnp.36.3.354.
Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less beneficial to patients who had previously received amantadine, whereas amantadine became effective in patients who had previously taken L-dopa. The effect of pre-treatment with one drug on the therapeutic effectiveness of the other drug is reflected in changes of homovanillic acid levels in the cerebrospinal fluid.
27名帕金森病患者参与了左旋多巴和金刚烷胺的双盲交叉试验。每种药物给药六周，两个治疗阶段之间间隔六周。先服用左旋多巴的患者有明显改善，而先服用金刚烷胺的患者未观察到临床效果。左旋多巴对先前服用过金刚烷胺的患者效果较差，而金刚烷胺对先前服用过左旋多巴的患者有效。一种药物的预处理对另一种药物治疗效果的影响反映在脑脊液中高香草酸水平的变化上。
